Form 8-K PEREGRINE PHARMACEUTICAL For: Dec 09

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC� 20549

�

�

FORM 8-K

�

�

CURRENT REPORT

�

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

�

Date of Report (Date of earliest event reported): December 9, 2014

�

�

PEREGRINE PHARMACEUTICALS, INC.�

(Exact name of registrant as specified in its charter)

�

Delaware	�	0-17085	�	95-3698422
(State of other jurisdiction of incorporation)	�	(Commission File Number)	�	(IRS Employer Identification No.)
�	�	�	�	�

�

14282 Franklin Avenue, Tustin, California 92780
(Address of Principal Executive Offices)
�	�	�	�	�
Registrant’s telephone number, including area code: (714) 508-6000
�
Not Applicable
(Former name or former address, if changed since last report)

�

�

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

�

o����������� Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

o����������� Soliciting material pursuant to Rule 14A-12 under the Exchange Act (17 CFR 240.14a-12)

o����������� Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR.14d-2(b))

o����������� Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

�

�

�

�

Item 8.01 Other Events.

�

On December 9, 2014, Peregrine Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the declaration by the Company’s Board of Directors of a quarterly cash dividend payment of $0.65625 per share (the “Dividend”) on the Company’s 10.50% Series E Convertible Preferred Stock (the “Series E Preferred Stock”), accruing from October 1, 2014 through December 31, 2014. The Dividend equates to an annualized 10.50% per share of Series E Preferred Stock based on the $25.00 per share stated liquidation preference. The Dividend on the Series E Preferred Stock is payable on January 2, 2015 to holders of record at the close of business on December 19, 2014. A copy of the press release is filed hereto as Exhibit 99.1.

�

�

Item 9.01 Financial Statements and Exhibits.

�

(d) Exhibits. The following material is filed as an exhibit to this Current Report on Form 8-K:

�

�

Exhibit

Number

�

�

99.1���������� Press Release issued December 9, 2014.

�

�

SIGNATURES

�

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

�

�	PEREGRINE PHARMACEUTICALS, INC.
�	�
�	�
�	�
Date: December 9, 2014	By:�����/s/ Paul J. Lytle
�	Paul J. Lytle
�	Chief Financial Officer

�

�

�

�

�

�

�

�

�

�

�

�

�

EXHIBIT INDEX

�

�

Exhibit	�
Number	Description
�	�
99.1	Press Release issued December 9, 2014.

�

�

�

�

�

�

�

�

�

�

�

�

�

�

�

Exhibit 99.1

�

Exhibit 99.1

�

Contact:
Christopher Keenan
Peregrine Pharmaceuticals, Inc.
(800) 987-8256

[email protected]

�

�

Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock

�

TUSTIN, CA – December 9, 2014 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock").

�

The quarterly dividend on the Series E Preferred Stock is payable on January 2, 2015 to holders of record at the close of business on December 19, 2014.

�

The quarterly dividend payment on the Series E Preferred Stock will be $0.65625 per share, which is equivalent to an annualized 10.50% per share, based on the $25.00 per share stated liquidation preference, accruing from October 1, 2014 through December 31, 2014. The Series E Preferred Stock is listed on the NASDAQ Capital Market and trades under the ticker symbol "PPHMP".

�

About Peregrine Pharmaceuticals, Inc.

�

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a pipeline of novel drug candidates in clinical trials for the treatment and diagnosis of cancer. The company's lead immunotherapy candidate, bavituximab is in Phase III development for the treatment of second-line non-small lung cancer (the "SUNRISE trial") along with several investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. The company is also advancing a molecular imaging agent, 124I-PGN650, in an exploratory clinical trial for the imaging of multiple solid tumor types. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. Additional information about Peregrine can be found at www.peregrineinc.com.

�

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Interra Provides Rip Copper Molybdenum Project Exploration Update
• Introducing Altcat: Your AI Girlfriend Experience with Your Favorite Influencer
• Future Works Announces Official Launch: Unlocking Leaps in Innovation with Bespoke AI Solutions